Telix Pharmaceuticals

TLX

Market cap $3.62B

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.

NEW YORK , Oct. 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in  Telix and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Telix Pharmaceuticals (NASDAQ:TLX) updated on Tuesday its commercial and operational performance for the third quarter of fiscal 2025.

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise.

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., October 12, 2025. Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.

NEW YORK , Oct. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.

NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.

NEW YORK , Oct. 3, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.